<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645890</url>
  </required_header>
  <id_info>
    <org_study_id>150BPH15022</org_study_id>
    <nct_id>NCT02645890</nct_id>
  </id_info>
  <brief_title>Study to Compare the Safety and Pharmacokinetics of CKD-397</brief_title>
  <acronym>CKD-397</acronym>
  <official_title>A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Profiles of CKD-397 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397&#xD;
      in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, oral single dosing, two-way crossover clinical trial to evaluate&#xD;
      the safety and pharmacokinetic profiles of CKD-397 in healthy male subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Tadalafil/ Tamsulosin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>CKD-397</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tadalafil/ Tamsulosin Fixed dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD+TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil/ Tamsulosin Coadministration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-397</intervention_name>
    <description>Arm A:Tamsulosin/ Tadalafil Fixed dose combination</description>
    <arm_group_label>CKD-397</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD+TM</intervention_name>
    <description>Arm B: Tamsulosin/ Tadalafil Coadministration</description>
    <arm_group_label>TD+TM</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. More than 19 years in Healthy male volunteer&#xD;
&#xD;
          2. Body weight ≥ 55kg and in the range of calculated BMI 17.5 to 30.5kg/m2&#xD;
&#xD;
          3. Subject who signed on an informed consent form willingly&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant disease with hematological, nephrological, respiratory,&#xD;
             gastrointestinal, urogenital, cardiovascular, psychiatric, neurologic system and&#xD;
             allergic disease (except for non-symptom seasonal allergy)&#xD;
&#xD;
          2. Gastrointestinal disease(esophageal achalasia, esophagus stenosis, crohn's disease) or&#xD;
             gastrointestinal surgery(except for appendectomy or herniotomy)&#xD;
&#xD;
          3. Aspartate aminotransferase, Alanine aminotransferase &gt; 2 X upper limit of normal range&#xD;
             or eGFR which is calculated by MDRD(Modification of diet in renal disease) &lt;&#xD;
             60mL/min/1.73m2&#xD;
&#xD;
          4. Continuously taking excessive alcohol(&gt;210g/week) within 6 months before screening&#xD;
&#xD;
          5. Have received any other investigational drug within 3 months prior to the first dosing&#xD;
&#xD;
          6. Sitting systolic blood pressure ≤ 100mmHg or ≥ 150mmHg, sitting diastolic blood&#xD;
             pressure ≤ 60mmHg or ≥ 100mmHg&#xD;
&#xD;
          7. Subject with orthostatic hypotension&#xD;
&#xD;
          8. The history of drug abuse or drug abuse showed a positive for urine drug test&#xD;
&#xD;
          9. Subject who takes inducers or inhibitors of drug metabolizing enzyme within 30 days&#xD;
&#xD;
         10. Cigarette ≥ 20 cigarettes a day for recent 3 months and Subject who cannot stop&#xD;
             smoking during clinical trial participation&#xD;
&#xD;
         11. Subject who takes ethical drug or herbal medicine within 2 weeks or over-the-counter&#xD;
             drug or vitamins within 1 week&#xD;
&#xD;
         12. Whole blood donation within 2 months or component blood donation within 1 month or&#xD;
             blood transfusion within 1 month prior to the first dosing&#xD;
&#xD;
         13. Subject who can increase risk due to clinical test and administration of drugs or has&#xD;
             severe grade / chronic medical, mental condition or abnormal laboratory result that&#xD;
             may interfere with the analysis of test results.&#xD;
&#xD;
         14. Subject with taking any forms of organic nitrate periodically and/or intermittently.&#xD;
&#xD;
         15. Subject with known hereditary degenerative retinal disease including retinitis&#xD;
             pigmentosa.&#xD;
&#xD;
         16. Subject with serious history of hypersensitivity to investigational product (including&#xD;
             Tadalafil and Tamsulosin) and other medicine (aspirin, antibiotics and so on)&#xD;
&#xD;
         17. Subject who lost sight of one eye by non-arteritic anterior ischemic optic neuropathy&#xD;
             (NAION, non-arteritic anterior ischemic optic neuropathy).&#xD;
&#xD;
         18. Subject with genetic problems such as galactose intolerance, fructose intolerance,&#xD;
             lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase&#xD;
             insufficiency&#xD;
&#xD;
         19. Subject who planned pregnancy during clinical trial and doesn't use trustworthy&#xD;
             contraception&#xD;
&#xD;
         20. Subjects who is not able to comply with guidelines described in the protocol.&#xD;
&#xD;
         21. An impossible one who participants in clinical trials by investigator's decision&#xD;
             including laboratory test result or another reason&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Kyu Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>9F, DongA University Hospital Department of clinical pharmacology, #26, Daechingongwon-ro, seo-gu, busan, 49201, KOREA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dong A University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Healthy Male Volunteer</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Tadalafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

